MTIP closes second health-tech growth fund at $250 million

Please login or
register
07.12.2021
MTIP Team

MTIP, the Swiss health-tech focused private equity firm, has today announced the closing of its MTIP Fund II, SCSp at USD $250 million in capital commitments. The oversubscribed fund closed above its target of $225 million with capital raised from new and existing investors, including multiple renowned institutional investors, pension funds, family offices, hospitals, and foundations. 

The fund, which is one of the few health-tech-specific private equity funds focused on Europe, provides growth capital to entrepreneurial and fast-growing digital health and digitally-connected medical device companies. MTIP Fund II seeks to capitalise on Europe’s rapidly expanding health-tech landscape, providing up to €25 million in funding to help promising scale-up companies become global leaders. The company has already made five investments out of its second fund one of them in the Swiss company Oviva.

After a strong first closing in late March of this year, MTIP has completed the final closing of its second fund above its original target with capital raised from new and existing investors, including multiple renowned institutional investors, pension funds, family offices, hospitals, and foundations. Andreas Schönenberger, CEO at the Swiss health insurance company Sanitas, is one of the investors in MTIP Fund II. He commented: “MTIP has unique expertise in health-tech and fosters innovation in this under-served private equity sector. Our collaboration with MTIP gives us access to innovative health-tech solutions that enable us to generate added value for our customers.”

“We are excited to announce the successful closing of our second fund and continue our mission to build the healthtech leaders of tomorrow,” said Dr. Christoph Kausch, Managing Partner at MTIP. “The trust our investors have put in us is a great endorsement of our strategy that’s built on our singular focus and proven approach to value creation.”

(Press release / SK)

0Comments

rss